FeesSafety
Pluang+

Rocket Pharmaceuticals' price target cut to $2.95 amid gene therapy progress and new funding.

Analyst Insights
07 Oct 2026, 17:04 WIB
Danny Green
View Source
Bearish
Rocket Pharmaceuticals' price target cut to $2.95 amid gene therapy progress and new funding.

Jefferies analyst Andrew Tsai lowered Rocket Pharmaceuticals' price target to $2.95, with shares trading at $2.48. The company is advancing its gene therapy for Danon disease, RP-A501, with an FDA-aligned pivotal study plan. Rocket secured $35 million in funding, extending its cash runway into Q3 2028, potentially longer with more borrowing. This funding supports ongoing development of treatments for rare diseases, though no trial results were disclosed yet.

Rocket Pharmaceuticals' recent funding of $35 million extends its cash runway into Q3 2028. For readers following the health sector, here is Pluang's market snapshot as of Oct 07, 2026 20:05 WIB: out of 100 priced US health stocks, 46 rose and 50 fell. Notable movers include Heron Therapeutics Inc (HRTX) up 2.50% at USD 0.34 with 54% sell order activity, Mesoblast Limited (MESO) up 2.35% at USD 13.93, and Danaher Corporation (DHR) up 2.06% at USD 220.01.

More News

Realty Income REIT offers a 5.6% yield amid easing rate fears and steady retail tenants.

Realty Income REIT offers a 5.6% yield amid easing rate fears and steady retail tenants.

Realty Income, a real estate investment trust specializing in retail properties, currently offers a forward dividend yield of 5.6%. Despite concerns about rising interest rates and economic pressures, its strong tenant base including Walmart and Walg...

Market News
Bullish
1 hour ago
Valvoline posts 22% Q4 sales growth, surpasses $4B annual sales with strong store expansion.

Valvoline posts 22% Q4 sales growth, surpasses $4B annual sales with strong store expansion.

Valvoline reported a 22% increase in net sales to $555 million in Q4 2026 and achieved over $4 billion in annual system-wide sales across 2,517 stores. The company marked its 20th consecutive year of same-store sales growth, driven by price adjustmen...

Company Fundamentals
Bullish
1 hour ago
SpaceX shares drop 4% as Anthropic's IPO rally fades, revealing risks tied to a $120B contract.

SpaceX shares drop 4% as Anthropic's IPO rally fades, revealing risks tied to a $120B contract.

SpaceX stock fell 4% after Anthropic's AI company IPO initially surged but then declined, dampening the tech market rally. Anthropic, a major customer of SpaceX's AI division, has committed up to $120.5 billion for computing capacity through 2029, wi...

Market News
Bearish
1 hour ago
Nvidia, Amazon, and Alphabet poised to benefit from Anthropic's AI IPO success.

Nvidia, Amazon, and Alphabet poised to benefit from Anthropic's AI IPO success.

Anthropic's recent IPO has generated excitement, but some investors prefer to wait for more financial data before investing directly. Nvidia, Amazon, and Alphabet stand to gain significantly from Anthropic's growth, as Nvidia supplies key AI hardware...

Market News
Bullish
1 hour ago
Bath & Body Works beats sales expectations with $1.6B Q3, launches new products, and saves $200M in costs.

Bath & Body Works beats sales expectations with $1.6B Q3, launches new products, and saves $200M in costs.

Bath & Body Works reported $1.6 billion in net sales for Q3 2026, surpassing management's guidance. The company is successfully launching new product franchises like Essentials and Everyday Luxuries, which are driving higher repeat customer purchases...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App